Rationale and design of LAPLACE-2: A phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy

Jennifer G. Robinson; William J. Rogers; Bettina S. Nedergaard; Jonathan Fialkow; Joel M. Neutel; David Ramstad; Ransi Somaratne; Jason C. Legg; Patric Nelson; Rob Scott; Scott M. Wasserman; Robert Weiss

doi:10.1002/clc.22252

Rationale and design of LAPLACE-2: A phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy

Jennifer G. Robinson
, William J. Rogers
, Bettina S. Nedergaard
, Jonathan Fialkow
, Joel M. Neutel
, David Ramstad
, Ransi Somaratne
, Jason C. Legg
, Patric Nelson
, Rob Scott
, Scott M. Wasserman
, Robert Weiss

FIU Herbert Wertheim College of Medicine, Miami, FL

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	195-203
Number of pages	9
Journal	Clinical Cardiology
Volume	37
Issue number	4
DOIs	https://doi.org/10.1002/clc.22252
State	Published - Apr 2014

ASJC Scopus Subject Areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1002/clc.22252

Cite this

Robinson, J. G., Rogers, W. J., Nedergaard, B. S., Fialkow, J., Neutel, J. M., Ramstad, D., Somaratne, R., Legg, J. C., Nelson, P., Scott, R., Wasserman, S. M., & Weiss, R. (2014). Rationale and design of LAPLACE-2: A phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. Clinical Cardiology, 37(4), 195-203. https://doi.org/10.1002/clc.22252

Rationale and design of LAPLACE-2: A phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. / Robinson, Jennifer G.; Rogers, William J.; Nedergaard, Bettina S. et al.
In: Clinical Cardiology, Vol. 37, No. 4, 04.2014, p. 195-203.

Research output: Contribution to journal › Article › peer-review

Robinson, JG, Rogers, WJ, Nedergaard, BS, Fialkow, J, Neutel, JM, Ramstad, D, Somaratne, R, Legg, JC, Nelson, P, Scott, R, Wasserman, SM & Weiss, R 2014, 'Rationale and design of LAPLACE-2: A phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy', Clinical Cardiology, vol. 37, no. 4, pp. 195-203. https://doi.org/10.1002/clc.22252

Robinson JG, Rogers WJ, Nedergaard BS, Fialkow J, Neutel JM, Ramstad D et al. Rationale and design of LAPLACE-2: A phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. Clinical Cardiology. 2014 Apr;37(4):195-203. doi: 10.1002/clc.22252

@article{fb12591133de4b518fcc745dfe0e9df2,

title = "Rationale and design of LAPLACE-2: A phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy",

author = "Robinson, \{Jennifer G.\} and Rogers, \{William J.\} and Nedergaard, \{Bettina S.\} and Jonathan Fialkow and Neutel, \{Joel M.\} and David Ramstad and Ransi Somaratne and Legg, \{Jason C.\} and Patric Nelson and Rob Scott and Wasserman, \{Scott M.\} and Robert Weiss",

year = "2014",

month = apr,

doi = "10.1002/clc.22252",

language = "English",

volume = "37",

pages = "195--203",

journal = "Clinical Cardiology",

issn = "0160-9289",

number = "4",

}

TY - JOUR

T1 - Rationale and design of LAPLACE-2

T2 - A phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy

AU - Robinson, Jennifer G.

AU - Rogers, William J.

AU - Nedergaard, Bettina S.

AU - Fialkow, Jonathan

AU - Neutel, Joel M.

AU - Ramstad, David

AU - Somaratne, Ransi

AU - Legg, Jason C.

AU - Nelson, Patric

AU - Scott, Rob

AU - Wasserman, Scott M.

AU - Weiss, Robert

PY - 2014/4

Y1 - 2014/4

UR - https://www.scopus.com/pages/publications/84899102691

UR - https://www.scopus.com/pages/publications/84899102691#tab=citedBy

U2 - 10.1002/clc.22252

DO - 10.1002/clc.22252

M3 - Article

C2 - 24481874

AN - SCOPUS:84899102691

SN - 0160-9289

VL - 37

SP - 195

EP - 203

JO - Clinical Cardiology

JF - Clinical Cardiology

IS - 4

ER -

Rationale and design of LAPLACE-2: A phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy

ASJC Scopus Subject Areas

Access to Document

Other files and links

Cite this